VELO Veloxis Pharmaceuticals A/S

Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S

Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S

Company Release no. 12/2020

To: NASDAQ Copenhagen A/S                                                

Copenhagen, Denmark, 29 January 2020



Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S



As announced in company release no. 10/2020, Veloxis Pharmaceuticals A/S ("Veloxis") has, upon request from Asahi Kasei Pharma Denmark A/S, requested Nasdaq Copenhagen A/S ("Nasdaq Copenhagen") to remove Veloxis' shares from trading and official listing at Nasdaq Copenhagen.

Nasdaq Copenhagen has accepted the request. Consequently, the last of trading and official listing of the shares in Veloxis (ISIN DK0060048148) on Nasdaq Copenhagen will be Monday 24 February 2020.



For more information, please contact:

Craig A. Collard             Ira Duarte                               

CEO                              CFO     

Phone:                                

Email:                          

This announcement has been prepared both in English and Danish. In the event of any discrepancies between the English and Danish version, the English version shall prevail.



About Veloxis

Veloxis is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit .

Attachment

EN
29/01/2020

Underlying

VELOVeloxis Pharmaceuticals A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Veloxis Pharmaceuticals A/S

 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 Febru...

Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Company Release no. 13/2020 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 17 February 2020 Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Today, Veloxis Pharmaceuticals A/S' Extraordinary General Meeting passed the following resolutions: The following persons were elected as members of the Board of Directors: Masaya EtohDaisuke MatsuoMatthew Ryan Dumont                    The elected board members replace all current membe...

February 17, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmace...

Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Selskabsmeddelelse nr. 12/2020 Til: NASDAQ Copenhagen A/S                                                  København, Danmark, 29. januar 2020   Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S   Som meddelt ved selskabsmeddelelse nr. 10/2020 har Veloxis Pharmaceuticals A/S ("Veloxis"), eft...

January 29, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Reques...

Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S Company Release no. 12/2020 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 29 January 2020 Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S As announced in company release no. 10/2020, Veloxis Pharmaceuticals A/S ("Veloxis") has, upon request from Asahi Kasei Pharma Denmark A/S, requested Nasdaq Copenhagen A/S ("Nasdaq Cop...

January 29, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Notice to Convene Extraordinary General Meeting

Notice to Convene Extraordinary General Meeting Company Announcement no. 11/2020 To: NASDAQ Copenhagen A/S                                           Copenhagen, Denmark, 24 January 2020 Notice to Convene Extraordinary General Meeting Upon request from Asahi Kasei Pharma Denmark A/S, the board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 (the "Company"), hereby convenes an extraordinary general meeting in the Company to be held on Monday 17 February 2020 at 12:00 p.m. CET at the offices o...

January 24, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceutical...

Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Selskabsmeddelelse nr. 10/2020 Til: NASDAQ Copenhagen A/S                                                  København, Danmark, fredag den 24. januar 2020 Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Med henvisning til selskabsmeddelelse nr. 9/2020, i hvilken Asahi Kasei Pharma Denmark A/S offentliggjorde sin beslutning om at udnytte sin ret til at gennemføre en tvangsindløsning af aktierne ejet af Vel...

January 24, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch